Reader’s Guide Clomazone

CRM: Casey Jarvis

EPA/OPPTS/OPP/SRRD

Reader’s Guide to Clomazone Docket # OPP-2006-0113

Publication Date: January 31, 2007

EPA has created this document to provide an organizational structure to
the Clomazone docket. The docket index lists the caption entries
sequentially, while this document lists them by subject matter. The
Agency is providing the “Readers Guide” to allow the reader to more
easily access and navigate the various entries contained in the
Clomazone.

Federal Register and Docket Organizational Documents:

Docket Entry 1. Federal Register Notice:  Clomazone Reregistration
Review

Docket Entry 2.  Reader’s Guide to Clomazone Docket # OPP-2006-0113

Docket Entry 3.  Clomazone-Acute and Chronic Dietary Exposure Analyses

Docket Entry 4.  Water Memorandum for Clomazone Incorporating both
Parent Clomazone and the  Metabolite FMC

Docket Entry 5. Section 3-Amended Registration for Clomazone

Docket Entry 6.  Section 24c Special Local Need Request for Clomazone

Docket Entry 7. Clomazone (Command 3ME) in/on Mint. HED Risk Assessment

Docket Entry 8.  Clomazone-Exposure/Risk Assessment from the Proposed
New Use of Clomazone on Mint

Docket Entry 9.  67 FR 54124

Docket Entry 10.  Clomazone Report of Hazard Identifcation Assessment
Review Committee

Docket Entry 11.    Review of Clomazone Incident Reports

Docket Entry 12.   Occupational and Residential Exposure and Risk
         Assessment/Characterization for the Proposed Use of Clomazone
on Sugarcane

Docket Entry 13.  Glossary of Terms and Abbreviations

Docket Entry 14.  Clomazone Tolerance Table

Docket Entry 15.  Clomazone Appendix A 2006

Docket Entry 16.  OPP Standard Operating Procedure: Inclusion of Water
Quality & Impaired Water Body Data in OPP’s Registration Review Risk
Assessment & Management Process

Docket Entry 17.  Clomazone Summary Document final 1/23/2007

Docket Entry 18.  Review of Environmental Fate and Ecological Effects
for Section 3 and Proposed new uses and Other Communications on
Clomazone


[Federal Register Volume 83, Number 176 (Tuesday, September 11, 2018)]
[Notices]
[Page 45932]
[FR Doc No: 2018-19768]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[CERCLA-04-2018-3755; FRL-9983-48--Region 4]

J.J. Seifert Machine Shop Superfund Site, Sun City, Hillsborough
County, Florida; Notice of Settlement

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice of settlement.

-----------------------------------------------------------------------

SUMMARY: Under 122(h) of the Comprehensive Environmental Response,
Compensation and Liability Act (CERCLA), the United States
Environmental Protection Agency has entered into a settlement
concerning the J.J. Seifert Machine Shop Superfund Site located in Sun
City, Hillsborough County, Florida with the following parties: U B
Corp, the Robert J. Upcavage Family Trust and Lawrence J. Bauer, Jr.
The settlement addresses recovery of CERCLA costs for a cleanup action
performed by the EPA at the Site.

DATES: The Agency will consider public comments on the settlement until
October 11, 2018. The Agency will consider all comments received and
may modify or withdraw its consent to the proposed settlement if
comments received disclose facts or considerations which indicate that
the proposed settlement is inappropriate, improper, or inadequate.

ADDRESSES: Copies of the settlement are available from the Agency by
contacting Ms. Paula V. Painter, Program Analyst, using the contact
information provided in this notice. Comments may also be submitted by
referencing the Site's name through one of the following methods:
    Internet: https://www.epa.gov/aboutepa/about-epa-region-4-southeast#r4-public-notices.
     U.S. Mail: U.S. Environmental Protection Agency, Superfund
Division, Attn: Paula V. Painter, 61 Forsyth Street SW, Atlanta,
Georgia 30303.
     Email: [email protected].

FOR FURTHER INFORMATION CONTACT: Paula V. Painter at 404/562-8887.

    Dated: July 30, 2018.
Greg Armstrong,
Acting Chief, Enforcement and Community Engagement Branch, Superfund
Division.
[FR Doc. 2018-19768 Filed 9-10-18; 8:45 am]
 BILLING CODE 6560-50-P


			  UNITED STATES OF AMERICA

		        DEPARTMENT OF TRANSPORTATION

			  OFFICE OF THE SECRETARY

			          WASHINGTON, D.C.

Issued by the Department of Transportation on May 15, 2003

NOTICE OF ACTION TAKEN -- DOCKET OST 2003-14889

________________________________________________________________________
________________________________________________________

This serves as notice to the public of the action described below, taken
by the Department official indicated (no additional confirming order
will be issued in this matter).

Applicant:  ANTONOV DESIGN BUREAU
                           Date Filed:  April 7, 2003

Relief requested:  Exemption from 49 U.S.C. section 40109(g) to permit
the applicant to operate one, one-way, cargo charter flight from
Richmond, VA, to Bismarck, ND, during the period June 1-30, 2003, using
its AN-124 aircraft to transport an outsized turbine rotor/trailer unit
and ancillary equipment, on behalf of CAP Logistics, Inc., acting on
behalf of Basin Electric Power Cooperative (Basin Electric).  The
applicant stated that Basin Electric urgently needed to move the turbine
late April 2003 to Richmond for reconditioning (that portion of the
applicant’s request was granted on April 15, 2003, in this Docket),
and to return it to Bismarck in June 2003 in order to restore a power
plant to full service.  It stated that the size and weight of the rotor,
coupled with the distance involved, foreclosed the possibility of
transporting the unit on a timely and reasonably safe basis by surface
transportation.  The applicant further stated that in order to avoid
undue delays to the rotor’s reconditioning and return to service, and
possible service disruptions for Basin Electric’s customers, the rotor
needed to be shipped by air, and that the unit is too large for
transportation on U.S. carrier aircraft.

Applicant representative:  Sheryl Israel,<PHONE_NUMBER>             DOT
analyst:  Allen F. Brown,<PHONE_NUMBER>

Responsive pleadings:  Antonov served its application on those U.S.
carriers operating large all-cargo aircraft.  Each carrier indicated
that it did not have aircraft available to conduct the proposed
operations and that it had no comment or did not oppose grant of the
requested authority to Antonov.

Statutory Standards:  Under 49 U.S.C. section 40109(g), we may authorize
a foreign air carrier to carry commercial traffic between U.S. points
(i.e., cabotage traffic) under limited circumstances.  Specifically, we
must find that the authority is required in the public interest; that
because of an emergency created by unusual circumstances not arising in
the normal course of business the traffic cannot be accommodated by U.S.
carriers holding certificates under 49 U.S.C. section 41102; that all
possible efforts have been made to place the traffic on U.S. carriers;
and that the transportation is necessary to avoid unreasonable hardship
to the traffic involved (an additional required finding, concerning
emergency transportation during labor disputes, was not relevant here).
For examples of earlier grants of authority of this type, see, i.e.,
Order 2001-5-23.

        DISPOSITION

Action: Approved
                                               Action date:  May 15,
2003

Effective dates of authority granted:  June 1-30, 2003

Basis for approval:  We are granting Antonov’s request to operate its
proposed flight from Richmond to Bismarck, during the period June 1-30,
2003.  We found that its request met all the relevant criteria of 49
U.S.C. section 40109(g) for the grant of an exemption of this type and
that the grant was required in the public interest.  Specifically, we
were persuaded that the need to move the cargo back to Bismarck in June
to meet Basic Electric’s schedule to restore an electrical power plant
to full services as soon as possible; the fact that the cargo could not
be transported by other modes in time promptly to meet the restoration
schedule; the potential negative impact of delivery delay; and the
unique, outsized nature of the cargo, constituted an emergency not
arising in the normal course of business.  Moreover, based on the
representations of the U.S. carriers, we concluded that no U.S. carrier
had aircraft available which could be used to conduct the operation at
issue here.  Finally, we found that the applicant was qualified to
perform its proposed operation (see, e.g., Notice of Action Taken dated
August 26, 2002, in Docket OST-96-1454).

Except to the extent exempted/waived, this authority is subject to our
standard exemption conditions and to the condition that the applicant
must comply with an FAA-approved flight routing for the authorized
flight.

Action taken by:      Read C. Van de Water

                                  Assistant Secretary for Aviation

                                     and International Affairs

An electronic version of this document is available on the World Wide
Web at:

http://dms.dot.gov//reports/reports_aviation.asp


[Federal Register Volume 81, Number 151 (Friday, August 5, 2016)]
[Notices]
[Pages 51917-51918]
[FR Doc No: 2016-18560]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice
of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming
public advisory committee meeting of the Cellular, Tissue, and Gene
Therapies Advisory Committee. The general function of the committee is
to provide advice and recommendations to the Agency on FDA's regulatory
issues. At least one portion of the meeting will be closed to the
public.

DATES: The meeting will be held on September 7, 2016, from 1 p.m. to 4
p.m.

ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. Answers to commonly asked questions including information
regarding special accommodations due to a disability, visitor parking,
and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

FOR FURTHER INFORMATION CONTACT: Janie Kim or Denise Royster, Center
for Biologics Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 301-
796-9016 or<PHONE_NUMBER><EMAIL_ADDRESS>or
<EMAIL_ADDRESS>or FDA Advisory Committee Information Line,
1-800-741-8138<PHONE_NUMBER> in the Washington, DC area). A notice in
the Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting. For those unable to attend in person, the meeting will
also be available via Webcast. The Webcast will be available at the
following link: https://collaboration.fda.gov/ctgtac0916/.

SUPPLEMENTARY INFORMATION:
    Agenda: On September 7, 2016, the committee will meet by
teleconference. In open session, the committee will hear updates of
research programs in the Gene Transfer and Immunogenicity Branch,
Division of Cellular and Gene Therapies, Office of Cellular, Tissue,
and Gene Therapies, Center for Biologics Evaluation and Research.
    FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
    Procedure: On September 7, 2016, from 1 p.m. to 2:20 p.m., the
meeting is open to the public. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Written submissions may be made to the contact person on
or before August 23, 2016. Oral presentations from the public will be
scheduled between approximately 2:20 p.m. to 3:20 p.m. Those
individuals interested in making formal oral presentations should
notify the contact person and submit a brief statement of the general
nature of the evidence or arguments they wish to present, the names and
addresses of proposed participants, and an indication of the
approximate time requested to make their presentation on or before
August 15, 2016. Time allotted for each presentation may be limited. If
the number of registrants requesting to speak is greater than can be
reasonably accommodated during the scheduled open public hearing
session, FDA may conduct a lottery to determine the speakers for the
scheduled open public hearing session. The contact person will notify
interested persons regarding their request to speak by August 16, 2016.
    Closed Committee Deliberations: On September 7, 2016, from 3:20
p.m. to 4 p.m., the meeting will be closed to permit discussion where
disclosure would constitute a clearly unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of
intramural research programs and make recommendations regarding
personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised
that the

Agency is not responsible for providing access to electrical outlets.
    FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Janie Kim at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).

    Dated: August 1, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special Medical Programs.
[FR Doc. 2016-18560 Filed 8-4-16; 8:45 am]
 BILLING CODE 4164-01-P


[Federal Register: December 5, 2005 (Volume 70, Number 232)]
[Notices]
[Page 72480-72483]
[DOCID:fr05de05-97]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-52851; File No. SR-CBOE-2005-84]

Self-Regulatory Organizations; Chicago Board Options Exchange,
Incorporated; Notice of Filing and Immediate Effectiveness of a
Proposed Rule Change and Amendment No. 1 Thereto Relating to
Transaction Fees for Options on the Dow Jones Industrial Average

November 29, 2005.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder,\2\ notice is hereby given that
on October 11, 2005, the Chicago Board Options Exchange, Incorporated
(``CBOE'' or ``Exchange'') filed with the Securities and Exchange
Commission (``Commission'') the proposed rule change as described in
Items I, II and III below, which Items have been prepared by the CBOE.
On November 22, 2005, the CBOE submitted Amendment No. 1 to the
proposed rule change.\3\ The CBOE

has designated this proposal as one establishing or changing a due,
fee, or other charge imposed by the CBOE under Section 19(b)(3)(A)(ii)
of the Act,\4\ and Rule 19b-4(f)(2) thereunder,\5\ which renders the
proposal effective upon filing with the Commission.\6\ The Commission
is publishing this notice to solicit comments on the proposed rule
change, as amended, from interested persons.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
    \3\ In Amendment No. 1, the Exchange revised the proposed rule
text to amend the fees assessed to non-member market-makers for
transactions in options on the Dow Jones Industrial Average (``DJX
options'') and in ``Jumbo'' options on the Dow Jones Industrial
Average (``DXL options''). The Exchange states that this change in
fees assessed to non-member market-makers for transactions in DJX
options and DXL options will be implemented on December 1, 2005.
    \4\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \5\ 17 CFR 240.19b-4(f)(2).
    \6\ The effective date of the original proposed rule change is
October 11, 2005, and the effective date of Amendment No. 1 is
November 22, 2005. For purposes of calculating the 60-day period
within which the Commission may summarily abrogate the proposed rule
change, as amended, under Section 19(b)(3)(C) of the Act, the
Commission considers the period to commence on November 22, 2005,
the date on which the Exchange submitted Amendment No. 1. See 15
U.S.C. 78s(b)(3)(C).
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The Exchange proposes to amend its Fees Schedule to: (i) Amend
certain fees for DJX options, and (ii) establish fees for DXL options.
The text of the proposed rule change is available on the Exchange's Web
site (http://www.cboe.com), at the Exchange's Office of the Secretary,

and at the Commission's Public Reference Room. The text of the proposed
rule change is also included below. Proposed new language is
italicized; proposed deletions are in [brackets].
CHICAGO BOARD OPTIONS EXCHANGE, INC.
FEES SCHEDULE
[OCTOBER 1, 2005] NOVEMBER 2, 2005
    1. OPTIONS TRANSACTION FEES (1)(3)(4)(7)(16): PER CONTRACT
    EQUITY OPTIONS (13):
    I.-IX. Unchanged.
    QQQQ and SPDR OPTIONS:
    I.-VII. Unchanged.
    INDEX OPTIONS (includes Dow Jones DIAMONDS, OEF and other ETF and
HOLDRs options) (17):

I. CUSTOMER (2):
     S&P 100, PREMIUM > or = $1......  $.35
     S&P 100, PREMIUM < $1...........  $.20
     DJX, MNX, [and] NDX, RUT and RMN  $.15
     [RUT and RMN....................  $.15]
     ETF and HOLDRs options..........  $.15
     OTHER INDEXES, PREMIUM > OR = $1  $.45
     OTHER INDEXES, PREMIUM < $1.....  $.25
II. MARKET-MAKER AND DPM (10): [--EXCLUDING
 DOW JONES PRODUCTS OTHER THAN DIA (10)$.24]
    [MARKET-MAKER--DOW JONES PRODUCTS (except  $.34]
     DIA) (10).
     DOW JONES PRODUCTS (except DIA    $.34
     and DJX).
     OTHER INDEXES...................  $.24
III. MEMBER FIRM PROPRIETARY: (11)
     FACILITATION OF CUSTOMER ORDER,   $.24
     MNX and NDX.
     FACILITATION OF CUSTOMER ORDER,   $.20
     OTHER INDEXES.
     NON-FACILITATION ORDER..........  $.24
IV. BROKER-DEALER (EXCLUDING THE PRODUCTS
 BELOW) INDEX CUSTOMER RATES.
     DJX, ETF (except DIA), HOLDRS,    $.45
     RUT and RMN, PREMIUM > or = $1.
     DJX, ETF (except DIA), HOLDRS,    $.25
     RUT and RMN, PREMIUM <  $1.
     DIA, MNX and NDX................  $.25
V. NON-MEMBER MARKET MAKER:
     DIA and DJX.....................  $.26
     DXL.............................  $.36
     S&P 100 (including OEF), PREMIUM  $.37
     > or = $1.
     S&P 100 (including OEF), PREMIUM  $.22
     <  $1.
     OTHER INDEXES, PREMIUM > or = $1  $.47
     OTHER INDEXES, PREMIUM < $1.....  $.27
VI.- IX. Unchanged.
2. MARKETING FEE (6)(16).....................  $.22
3. FLOOR BROKERAGE FEE (1)(5)(16)(17):
     EQUITY & QQQQ CUSTOMER ORDER....  $.00
     ALL OTHER EQUITY, QQQQ AND INDEX  $.04
     OPTIONS (8).
     CROSSED ORDERS..................  $.02
4. RAES ACCESS FEE (RETAIL AUTOMATIC
 EXECUTION SYSTEM) (1)(4)(16):
     INDEX CUSTOMER TRANSACTIONS.....  $.25
         DOW JONES, ASSESSED ON THE
         FIRST 25 CONTRACTS ONLY
     NON-CUSTOMER TRANSACTIONS         $.30
     (ORIGIN CODE OTHER THAN ``C'')(8)(9).
FOOTNOTES: Unchanged.
5.-6. Unchanged.
7. INDEXES CUSTOMER ORDER BOOK OFFICIAL (OBO)
 EXECUTION FEES(16)(17):

                                                 Rate Per Contract (1)

    Accommodation Liquidation Or Cabinet       $.10
     Order.
    All Other Orders.........................   .25

    (1) OEX--No charge for ``market'' and ``limit orders'' placed with
the OBO prior to the opening and executed during opening rotation.
    Other Indexes--Same as above for index ``market orders'' (``limit
orders'' not included).

    Remainder of Fees Schedule--Unchanged.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, the Exchange included statements
concerning the purpose of, and basis for, the proposed rule change, as
amended, and discussed any comments it received on the proposed rule
change, as amended. The text of these statements may be examined at the
places specified in Item IV below. The Exchange has prepared summaries,
set forth in Sections A, B, and C below, of the most significant
aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

1. Purpose
    The Exchange proposes to amend its Fees Schedule to reduce and
eliminate certain fees for DJX options and to establish fees for DXL
options.
    a. DJX Options Fees. The Exchange proposes to reduce customer and
non-member market-maker fees for transactions in DJX options and
eliminate the market-maker license fee surcharge applicable to
transactions in DJX options.
    Currently, customer transaction fees for transactions in DJX
options are $.45 if the premium is greater than or equal to $1 and $.25
if the premium is less than $1. The Exchange proposes to reduce fees
for public customer transactions in DJX options to $.15 per contract.
Moreover, the transaction fees for non-member market-maker transactions
in DJX options are currently $.47 per contract if the premium is
greater than or equal to $1 and $.27 per contract if the premium is
less than $1. The Exchange proposes to reduce the non-member market
maker transaction fee for transactions in DJX options to $.26 per
contract, regardless of the premium.\7\
---------------------------------------------------------------------------

    \7\ See Amendment No. 1, supra note 3. According to CBOE, the
proposed change to the fees assessed to non-member market-makers for
transactions in DJX options will be implemented on December 1, 2005.
---------------------------------------------------------------------------

    In addition, the Exchange currently charges market-makers that
trade Dow Jones products, except options on DIAMONDS (``DIA''), a
license fee of $.10 per contract in addition to the regular transaction
fee of $.24 per contract, to assist the Exchange in offsetting some of
the royalty fees the Exchange must pay to Dow Jones for its license to
trade Dow Jones products.\8\ The Exchange proposes to eliminate the
$.10 license fee with respect to market-maker transactions in DJX
options.\9\
---------------------------------------------------------------------------

    \8\ See Securities Exchange Act Release No. 48223 (July 24,
2003), 68 FR 44978, 44979 (July 31, 2003).
    \9\ The Commission notes that the Exchange currently charges
market-makers that trade Dow Jones products, except DIA options, a
total fee of $.34 per contract, which reflects a $.10 licensing fee
surcharge. Under the proposed rule change, the fee for market-makers
that trade DJX options will be $.24 per contract.
---------------------------------------------------------------------------

    The Exchange is reducing these fees in connection with DJX options
moving to CBOE's Hybrid Trading System.\10\ The proposed fees changes
are intended to make DJX options competitively priced with respect to
DIA options.
---------------------------------------------------------------------------

    \10\ Conversation between Jaime Galvan, Assistant Secretary,
CBOE and Sara Gillis, Attorney, Division of Market Regulation,
Commission on November 23, 2005.
---------------------------------------------------------------------------

    b. DXL Options. The Exchange launched trading in DXL options on
October 11, 2005.\11\ DXL options are options that are based on one-
tenth the value of the Dow Jones Industrial Average (``DJIA'').\12\ DXL
options will trade in open outcry. The Exchange proposes to amend its
Fees Schedule to establish fees for DXL options.
---------------------------------------------------------------------------

    \11\ Id.
    \12\ DXL options are referred to as ``Jumbo-DJX'' options
because they are ten times larger than DJX options (DJX options are
based on 1/100th the value of the DJIA).
---------------------------------------------------------------------------

    Specifically, the Exchange proposes to assess public customers a
transaction fee for DXL options of $.45 if the premium is greater than
or equal to $1 and $.25 if the premium is less than $1. Market-maker
transaction fees for DXL options will be $.34, which consists of the
standard $.24 transaction fee and the $.10 license fee surcharge
assessed on certain Dow Jones index options as described above. Non-
member market-maker transaction fees for DXL options will be $.36,
regardless of the premium.\13\
---------------------------------------------------------------------------

    \13\ See Amendment No. 1, supra note 3. CBOE had originally
proposed to charge non-member market-makers a transaction fee for
transactions in DXL options of $.47 per contract if the premium was
greater than or equal to $1 and $.27 per contract if the premium was
less then $1. In Amendment No. 1, CBOE proposed to change the non-
member market-maker transaction fees for DXL options to $.36 per
contract, regardless of the premium. According to CBOE, the proposed
change to the fees assessed to non-member market-makers for
transactions in DXL options will be implemented on December 1, 2005.
---------------------------------------------------------------------------

    Member firm proprietary transaction fees for DXL options will be
$.20 for facilitation of customer orders and $.24 for non-facilitation
orders. Broker-dealer transaction fees for DXL options will be $.45 if
the premium is greater than or equal to $1 and $.25 if the premium is
less than $1.
    The floor brokerage fee for DXL options will be $.04, and for
crossed orders, the floor brokerage fee will be $.02. The RAES Access
Fee will be $.25 for customer transactions (only the first 25 contracts
will be assessed) and $.30 for non-customer transactions. Order Book
Official (``OBO'') execution fees will be $.10 per contract for cabinet
and accommodation/liquidation trades and $.25 per contract for all
other orders.
2. Statutory Basis
    The CBOE believes that the proposed rule change, as amended, is
consistent with Section 6(b) of the Act,\14\ in general, and furthers
the objectives of Section 6(b)(4) of the Act,\15\ in particular, in
that it is designed to provide for the equitable allocation of
reasonable dues, fees, and other charges among CBOE members and other
persons using its facilities.
---------------------------------------------------------------------------

    \14\ 15 U.S.C. 78f(b).
    \15\ 15 U.S.C. 78f(b)(4).
---------------------------------------------------------------------------

B. Self-Regulatory Organization's Statement on Burden on Competition

    The CBOE does not believe that the proposed rule change, as
amended, will impose any burden on competition that is not necessary or
appropriate in furtherance of the purposes of the Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed
Rule Change Received From Members, Participants or Others

    No written comments were solicited or received with respect to the
proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    The foregoing proposed rule change, as amended, has been designated
as a fee change pursuant to Section 19(b)(3)(A)(ii) of the Act \16\ and
Rule 19b-4(f)(2) \17\ thereunder, because it establishes or changes a
due, fee or other charge imposed by the Exchange. Accordingly, the
proposal will take effect upon filing with the Commission.\18\ At any
time within 60 days of the filing of the proposed rule change, as
amended, the Commission may summarily abrogate such rule change if it
appears to the Commission that such action is necessary or appropriate
in the public interest, for the protection of investors, or otherwise
in furtherance of the purposes of the Act.\19\
---------------------------------------------------------------------------

    \16\ 15 U.S.C. 78s(b)(3)(A)(ii).
    \17\ 17 CFR 240.19b-4(f)(2).
    \18\ See supra note 6.
    \19\ Id.

---------------------------------------------------------------------------

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change, as amended, is consistent with the Act. Comments may be
submitted by any of the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://www.sec.gov/rules/sro.shtml.
); or     Send an e-mail to<EMAIL_ADDRESS>Please include

File Number SR-CBOE-2005-84 on the subject line.

Paper Comments

     Send paper comments in triplicate to Jonathan G. Katz,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-9303.
    All submissions should refer to File Number SR-CBOE-2005-84. This
file number should be included on the subject line if e-mail is used.
To help the Commission process and review your comments more
efficiently, please use only one method. The Commission will post all
comments on the Commission's Internet Web site (http://www.sec.gov/rules/sro.shtml
). Copies of the submission, all subsequent amendments,

all written statements with respect to the proposed rule change, as
amended, that are filed with the Commission, and all written
communications relating to the proposed rule change, as amended,
between the Commission and any person, other than those that may be
withheld from the public in accordance with the provisions of 5 U.S.C.
552, will be available for inspection and copying in the Commission's
Public Reference Room. Copies of such filing also will be available for
inspection and copying at the principal office of the CBOE. All
comments received will be posted without change; the Commission does
not edit personal identifying information from submissions. You should
submit only information that you wish to make available publicly. All
submissions should refer to File Number SR-CBOE-2005-84 and should be
submitted on or before December 27, 2005.
---------------------------------------------------------------------------

    \20\ 17 CFR 200.30-3(a)(12).

    For the Commission, by the Division of Market Regulation,
pursuant to delegated authority.\20\
Jonathan G. Katz,
Secretary.
 [FR Doc. E5-6831 Filed 12-2-05; 8:45 am]

BILLING CODE 8010-01-P


  SEQ CHAPTER \h \r 1

Mr. Gary Barnett

Director, Environmental Compliance & Audit

Aleris International, Incorporated

25825 Science Park Drive, Suite 400

Beachwood, Ohio  44122-7392

Dear Mr. Barnett:

	Thank you for your efforts in assisting with the March 16, 2010, site
visit by U.S. Environmental Protection Agency (EPA) and RTI personnel to
the Aleris International facility in Morgantown, Kentucky. We appreciate
the time that you and other representatives at Aleris International set
aside for discussing and showing your manufacturing process.

	Enclosed is a draft of the trip report (Enclosure 1) that has been
prepared based on the information obtained during our site visit. We
would appreciate your reviewing the report for any errors or omissions.
You may return the enclosed copy of the report with your written
comments. Since this report will eventually become a part of the public
record, we want to portray your operations as accurately as possible. A
copy of the final version of the report incorporating your comments will
be sent to you for your records.

	The custody receipt for the trip report is also enclosed (Enclosure 2).
Please sign and date the form to acknowledge receipt of the report and
return a copy of the form to:

Mr. Roberto Morales; U.S. EPA Mailroom (C404-02); U.S. Environmental
Protection Agency;

Office of Air Quality Planning and Standards; 109 T.W. Alexander Drive;
Research Triangle Park, NC 27711.

	If you believe that disclosure of any specific information contained in
the trip report would reveal trade secrets or other confidential
information, you should clearly identify the specific information.
Please do not label the entire report as “confidential” if only
certain portions consist of trade secret information. If the EPA
determines that there is a need to disclose such information, we will
need, at that time, the following to support your claim:

	1. Measures taken by Aleris International to guard against undesired
disclosure of the specific information to others;

	2. The extent to which the specific information has been disclosed to
others and the precautions taken in connection therewith;

	3. Pertinent confidentiality determinations, if any, by other Federal
agencies (furnish a copy of any such determination, or reference to it,
if available); and

	4. Whether Aleris International asserts that disclosure of the specific
information would be likely to result in substantial harmful effects on
Aleris International’s competitive position, and, if so, what those
harmful effects would be, why they should be viewed as substantial, and
an explanation of the causal relationship between disclosure and such
harmful effects.

	Any specific information subsequently determined to constitute a trade
secret will be protected under 18 U.S.C. 1905. If no claim of
confidentiality accompanies the information when it is received by EPA,
it may be made available to the public by EPA without further notice (40
CFR Part 2.203, September 1, 1976). Any specific information
subsequently determined to constitute a trade secret will be protected
under 18 U.S.C. 1905. However, all emissions data will be available to
the public. A clarification of the information EPA considers to be
emissions data is contained in Enclosure 3.

	We respectfully request that you submit your review comments on the
trip report by August 26, 2010. If you concur with the information
contained in the report, we would appreciate a letter to that effect. In
addition, please indicate in your letter the specific parts of the
report, if any, that Aleris International considers to be confidential.
If we do not receive a response by August 26, 2010, the report will be
considered non-confidential and accurate.

	Thank you for your cooperation. The information supplied by Aleris
International will be most helpful in our study. If you have any
questions, please call Ms. Rochelle Boyd of my staff at<PHONE_NUMBER>,
or Mr. David Green at RTI at<PHONE_NUMBER>.

	Sincerely,

Susan Fairchild

Group Leader

Metals and Minerals Group

Office of Air Quality Planning and Standards

3 Enclosures

OAQPS/SPPD/MMG:RBoyd D243-02, 541-1390

(RTI/DGreen/316-3412/7/22/10)